Eleni Andreopoulou, M.D., completed her training in major academic institutions in both Europe and the U.S. In addition to her active clinical practice, her strength to the Weill Cornell Medicine team is her demonstrated passion for biomarker-driven clinical trials, pharmacogenomic predictors of chemoresistance, chemosensitivity, and endocrine sensitivity for early and advanced stage breast cancer. Most importantly, she conceptualized and established a prospective bio-repository in breast cancer providing a crucial foundation for precision medicine research.
At Weill Cornell Medicine, Dr. Andreopoulou actively facilitates the interface between basic and applied research and has a special interest in individualized patient treatment. Her main research interest is a biomarker-based patient selection in early phase development to fast track drug development of biologics and targeted therapy to effectively treat breast cancer while sparing patients from unnecessary toxicity. Her focus is next-generation oncology trials and incorporating technology in drug development. Her goal, in collaboration with scientists, is to explore the relationship between cancer treatment, neoplastic cells, and the immune system in order to improve understanding of the determinants of response to therapy. This has the potential to contribute critical information for future testing of combinations of immunotherapy and chemotherapy in breast cancer treatment.
She is an active investigator of several clinical trials of novel therapeutic approaches in advanced disease including her leadership role as a principal investigator in the development of agents sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute.
Dr. Andreopoulou has published over 40 peer review articles, reviews, editorials and book chapters and has been an invited speaker at international and national conferences. She is a member of several scientific organizations including the American Society of Clinical Oncology, the American Association of Cancer Research and the Royal Society of Medicine. She has also been active with Breast Cancer awareness programs covering screening and prevention with a particular focus on underserved minorities. She is also an active member of the American Women`s Medical Association.